When the X-ray Tells the Story: CRT-D and CCM in Advanced Heart Failure

Illustrative cover showing the different roles of heart-failure therapies. CRT resynchronizes ventricular activation; the defibrillator treats dangerous ventricular arrhythmias and reduces sudden-death risk. CCM may improve symptoms in selected patients, but evidence after CRT is limited. The original chest X-ray appears below.

Sometimes a chest X-ray tells the story before you even open the patient’s chart.

I want to present the case of an 85-year-old patient with ischemic cardiomyopathy, admitted again for heart-failure decompensation.

The X-ray immediately catches your attention.

A CRT-D on one side. A cardiac contractility modulation device on the other. And enough leads inside the heart to document years of progressively escalating heart-failure therapy.

But behind all that hardware is an important question:

What are we actually trying to achieve with each of these therapies?

The patient had already received CRT-D for advanced systolic heart failure.

CRT does something very specific. In the appropriately selected patient, it does not primarily make the myocardium “stronger.” It tries to make a dyssynchronous ventricle contract together again — coordinating right and left ventricular activation, improving mechanical efficiency and potentially inducing reverse remodeling.

The “D” adds another layer: protection against malignant ventricular arrhythmias and sudden cardiac death.

But not every patient responds sufficiently to resynchronization.

This patient remained symptomatic despite CRT and medical therapy.

So another concept was added: cardiac contractility modulation — CCM.

Evidence for adding CCM after CRT is limited. Most randomized CCM evidence comes from patients without a CRT indication, and a mortality benefit has not been established.

And CCM works very differently.

Instead of resynchronizing ventricular activation, it delivers electrical signals during the absolute refractory period. These signals do not trigger another heartbeat. Their purpose is to influence myocardial calcium handling and contractile biology, ultimately improving the strength and efficiency of contraction in selected patients with persistent HFrEF symptoms.

So when you look at this X-ray, you are essentially seeing two completely different electrophysiological strategies:

CRT: make the ventricle contract more synchronously.

CCM: modulate the myocardium to contract more effectively.

But there is a danger when looking at impressive device therapy.

We can start believing that heart failure has become a device disease.

It has not.

Underneath every lead and every generator, the foundation remains guideline-directed medical therapy.

For HFrEF, that means building treatment around the four pharmacological pillars whenever tolerated:

an ARNI — or ACE inhibitor/ARB when appropriate, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor.

Diuretics then do something different again: they do not replace prognostic therapy, but they are crucial when the patient in front of us is congested and needs recompensation. Contemporary HF guidance continues to place these four drug classes at the centre of HFrEF treatment.

And in an 85-year-old patient, “optimal” treatment does not necessarily mean forcing every medication to a textbook target dose.

Blood pressure matters. Renal function matters. Potassium matters. Frailty matters. Symptoms and quality of life matter.

The objective is not to create the most impressive medication list or implant the most sophisticated device.

The objective is to use every layer intelligently.

Medication changes the biology of heart failure. CRT can correct electrical and mechanical dyssynchrony. The ICD protects against sudden arrhythmic death. CCM may offer additional symptomatic and functional benefit in carefully selected patients who remain symptomatic despite established therapy. Current evidence for CCM is strongest around functional capacity and quality of life rather than the kind of mortality evidence we have for foundational HFrEF therapy and appropriately indicated CRT.

And then sometimes, despite all of it, the patient comes back decompensated.

That does not necessarily mean that everything before it has failed.

It reminds us what advanced heart failure really is:

a chronic disease in which treatment is built in layers — and every layer has a different job.

The X-ray looks complicated.

The principle behind it is actually quite simple:

Devices should complement good heart-failure medicine. They should never make us forget it.

#Cardiology #HeartFailure #HFrEF #CRT #CRTD #CCM #CardiacDevices #ClinicalCardiology